Estradiol enantate

Medical uses

Estradiol enantate is used in combination with the progestin DHPA as a once-monthly combined injectable contraceptive for women in Latin America and Hong Kong. Estradiol enantate has been studied in feminizing hormone therapy for transgender women as well. The combination of estradiol enantate and DHPA has likewise been used by transgender women for such purposes. Since at least the 2020s, it has grown in popularity among the transfeminine community as a means of DIY hormone therapy (without DHPA).

Available forms

The following forms of estradiol enantate are or have been available for use:

• Estradiol enantate 10 mg and DHPA 150 mg (brand names Perlutal, Topasel, many others)
• Estradiol enantate 5 mg and DHPA 75 mg (brand names Anafertin, Patector NF, Yectames)
• Estradiol enantate 10 mg and DHPA 120 mg (brand names Unalmes, Yectuna)
• Estradiol enantate 10 mg and DHPA 75 mg (brand name Ova Repos; discontinued)

A 6 mg estradiol enantate and 90 mg DHPA formulation was also studied, but was never marketed. The combination of estradiol enantate and DHPA has also been studied at other doses ranging from 5 to 50 mg estradiol enantate and 75 to 200 mg DHPA.

The combination of estradiol enantate and DHPA is provided in ampoules at estradiol enantate concentrations of 5 mg/mL and 10 mg/mL.

Contraindications

Contraindications of estrogens include coagulation problems, cardiovascular diseases, liver disease, and certain hormone-sensitive cancers such as breast cancer and endometrial cancer, among others.

Side effects

Main article: Estradiol (medication)#Side effects

The side effects of estradiol enantate are the same as those of estradiol. Examples of such side effects include breast tenderness and enlargement, nausea, bloating, edema, headache, and melasma. The combination of estradiol enantate and DHPA as a combined injectable contraceptive has shown no adverse effects on liver function, lipid metabolism, or coagulation.

A Brazilian case report of a prolactinoma in a transgender woman treated with 10 mg estradiol enantate every 2 weeks exists. While DHPA was not mentioned in this instance, estradiol enantate is normally formulated in combination with DHPA including in Brazil.

Overdose

Symptoms of estrogen overdosage may include nausea, vomiting, bloating, increased weight, water retention, breast tenderness, vaginal discharge, heavy legs, and leg cramps. These side effects can be diminished by reducing the estrogen dosage.

Interactions

Inhibitors and inducers of cytochrome P450 may influence the metabolism of estradiol and by extension circulating estradiol levels.

Pharmacology

Pharmacodynamics

Estradiol enantate is an estradiol ester, or a prodrug of estradiol. As such, it is an estrogen, or an agonist of the estrogen receptors. Estradiol enantate is of about 41% higher molecular weight than estradiol due to the presence of its C17β enantate ester. Because estradiol enantate is a prodrug of estradiol, it is considered to be a natural and bioidentical form of estrogen.

The combination of 10 mg estradiol enantate and 150 mg DHPA as a once-monthly combined injectable contraceptive (which achieves levels of estradiol of around 350 pg/mL) has been found to have little to no effect on many markers of estrogen-modulated liver protein synthesis, including circulating levels of HDL and LDL cholesterol, copper, ceruloplasmin, total and free cortisol, corticosteroid-binding globulin, and sex hormone-binding globulin. However, it was found to significantly increase levels of triglycerides and to significantly decrease levels of total and free testosterone. In contrast to the estradiol enantate-containing combined injectable contraceptive, low-dose ethinylestradiol-containing birth control pills produce highly significant changes in all of the preceding parameters.

Studies in women and female capuchin monkeys have found that injections of estradiol enantate and DHPA significantly alter levels of coagulation factors.

The clinical estrogenic effects of estradiol enantate and ethinylestradiol have been compared in other studies as well.

Pharmacokinetics

When estradiol enantate is administered in an oil solution by intramuscular injection, a depot effect occurs, and this results in it having a long duration of action. The duration of action of estradiol enantate is considerably longer than that of various other estradiol esters, such as estradiol benzoate and estradiol valerate, whereas its duration is shorter than that of estradiol undecylate. In general, the longer the fatty acid ester chain, the more lipophilic the estradiol ester, the more slowly it is released from the depot and absorbed into the circulation, and the longer its duration of action.

The pharmacokinetics of estradiol enantate have been assessed in a number of studies.-- It has usually been studied in combination with DHPA. Following an intramuscular injection of estradiol enantate, levels of estradiol have been found to peak after 3 to 8 days. Maximal levels of estradiol after a 5 mg injection of estradiol enantate have been found to be about 163 to 209 pg/mL and after a 10 mg injection of estradiol enantate have been found to be about 283 to 445 pg/mL. However, one outlying study reported peak estradiol levels of 850 pg/mL after an intramuscular injection of 10 mg estradiol enantate in three postmenopausal women. It used radioimmunoassay for the determinations, with no mention of chromatographic separation. Estradiol levels following an intramuscular injection of 10 mg estradiol enantate have been found to return to baseline levels of around 50 pg/mL after about 20 to 30 days. However, a metabolic study found that traces of radiolabeled estradiol enantate remained detectable in blood for at least 30 to 40 days and for as long as 60 days. Studies have reported that the elimination half-life of estradiol enantate after a single 10 mg intramuscular injection was 5.6 to 7.5 days. The volume of distribution of estradiol enantate has been reported to be 5.087 L. Estradiol enantate is excreted preferentially in urine.

There were concerns about possible accumulation of estradiol enantate and consequent estrogenic overexposure with once-monthly combined injectable contraceptives containing the medication due its long duration, and this may have limited the use of such combined injectable contraceptives. Subsequent clinical studies have found that there is very limited or no accumulation of estradiol enantate when it is used in once-a-month injectable contraceptives.

| Image:Estradiol levels after an intramuscular injection of different doses of estradiol enanthate in premenopausal women.png | class1=skin-invert-image | Estradiol levels after the most recent intramuscular injection during once-monthly 5 or 10 mg estradiol enanthate and 75 or 150 mg dihydroxyprogesterone acetophenide contraception in one premenopausal woman each. Assays were performed using radioimmunoassay. Source was Recio et al. (1986).

| Image:Estradiol levels after a single intramuscular injection of 10 mg estradiol enantate in postmenopausal women.png | class2=skin-invert-image | Estradiol levels after a single intramuscular injection of 10 mg estradiol enanthate in three postmenopausal women. Assays were performed using radioimmunoassay. Source was Wiemeyer et al. (1986).

| Image:Estradiol and prolactin levels after the last injection during therapy with estradiol enantate and dihydroxyprogesterone acetophenide in women.png | class3=skin-invert-image | Estradiol and prolactin levels after the most recent intramuscular injection during once-monthly 10 mg estradiol enanthate and 150 mg dihydroxyprogesterone acetophenide contraception in 10 premenopausal women. Only four determinations were made: days 0, 10, 20, and 30. Assays were performed using radioimmunoassay. Source was Garza-Flores et al. (1989).

| File:Estradiol levels with estradiol enanthate and dihydroxyprogesterone acetophenide after single or repeated injections in premenopausal women.png | class4=skin-invert-image | Simplified curves of estradiol levels after an intramuscular injection of 10 mg estradiol enanthate (E2-EN) and 150 mg dihydroxyprogesterone acetophenide (DHPA) in oil solution with single or continuous once-monthly use in women. Source was Garza-Flores (1994).

| File:Idealized curves of estradiol levels after injection of different estradiol esters in women.png | class5=skin-invert-image | Simplified curves of estradiol levels after injection of different estradiol esters in women. Source was Garza-Flores (1994).

Chemistry

Estradiol enantate, also known as estradiol 17β-enantate or estra-1,3,5(10)-triene-3,17β-diol 17β-heptanoate, is a synthetic estrane steroid and the C17β enantate (heptanoate) fatty acid ester of estradiol. Other common esters of estradiol used clinically include estradiol benzoate, estradiol cypionate, estradiol undecylate, and estradiol valerate. Estradiol dienantate (component of Climacteron), or estradiol 3,17β-dienantate, has also been used.

The experimental octanol/water partition coefficient (logP) of estradiol enanthate is 6.7.

History

Estradiol enantate was first described, along with a variety of other estradiol esters, by Karl Junkmann of Schering AG in 1953. The first clinical study of estradiol enantate and DHPA as a combined injectable contraceptive was conducted in 1964. The combination was marketed by the mid-1970s.

Society and culture

Generic names

Estradiol enantate is the British English generic name of the medication and its and , while estradiol enanthate is its and American English generic name. Its generic names in other languages are as follows:

• French: enantate d'estradiol and estradiol enantate
• German: estradiol enantat
• Italian: estradiolo enantato
• Portuguese and Spanish: enantato de estradiol and estradiol enantato

Estradiol enantate is also known by its former developmental code name SQ-16150. It has been referred to as estradiol heptanoate.

Brand names

Estradiol enantate has been marketed under a wide variety of brand names. It has been marketed in a few different preparations, with varying doses of estradiol enantate and DHPA. These formulations all have different brand names, which include the following († = discontinued):

• EEn 10 mg / DHPA 150 mg: Acefil, Agurin†, Atrimon†, Ciclomes, Ciclovar, Ciclovular, Cicnor†, Clinomin, Cycloven, Daiva, Damix, Deprans, Deproxone, Exuna, Ginestest, Ginoplan†, Gynomes, Horprotal, Listen, Luvonal, Neogestar, Neolutin, Nomagest, Nonestrol, Normagest, Normensil, Novular, Oterol, Ovoginal, Patector, Patectro, Perludil, Perlumes, Perlutal, Perlutale, Perlutan, Perlutin, Perlutin-Unifarma, Permisil, Preg-Less, Pregnolan, Progestrol†, Protegin, Proter, Seguralmes, Synovular, Topasel, Unigalen, Uno-Ciclo, and Vagital.
• EEn 10 mg / DHPA 120 mg: Anafertin†, Patector NF, and Yectames.
• EEn 5 mg / DHPA 75 mg: Unalmes and Yectuna.
• EEn 10 mg / DHPA 75 mg: Ova Repos†.
• Unsorted: Evitas†, Femineo†, and Primyfar†.

The combination of EEn 10 mg and DHPA 150 mg was developed under the developmental brand name Deladroxate, but this brand name was never used commercially.

Availability

Estradiol enantate has been marketed in combination with DHPA as a combined injectable contraceptive in at least 19 countries, mostly in Latin America. A few different preparations, with varying doses of EEn and DHPA and varying availability, have been introduced. These formulations have the following approval and availability († = discontinued in this country):

• EEn 10 mg / DHPA 150 mg: at least 19 countries, including Argentina, Belize, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Hong Kong, Mexico, Nicaragua, Panama, Paraguay, Peru, Portugal†, and Spain†.
• EEn 10 mg / DHPA 120 mg: at least 3 countries, including Brazil†, Chile, and Paraguay.
• EEn 5 mg / DHPA 75 mg: at least 9 countries, including Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, and Spain†.

EEn is also available in Canada in combination with estradiol benzoate and testosterone enantate for veterinary use as Uni-Bol.

Usage

EEn/DHPA is the most widely used combined injectable contraceptive in Latin America. It was estimated in 1995 that EEn/DHPA was used as a combined injectable contraceptive in Latin America by at least 1 million women. However, combined injectable contraceptives like EEn/DHPA are unlikely to constitute a large proportion of total contraceptive use in the countries in which they are available.

References

References

1. (June 2013). "Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment". Contraception.
2. (2007). "Clinical Reproductive Medicine and Surgery". Elsevier Health Sciences.
3. "Bula do Algestona Acetofenida + Enantato de Estradiol".
4. (September 1996). "Dihydroxyprogesterone acetophenide 150 mg + estradiol enantate 10 mg as monthly injectable contraceptives". Advances in Contraception.
5. (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control". World J Pharm Pharm Sci.
6. (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric.
7. (6 December 2012). "Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen". Springer Science & Business Media.
8. (15 December 2012). "Progress in Obstetrics and Gynecology--3". Jaypee Brothers Medical Publishers Pvt. Ltd..
9. (July 2024). "Hormones in Obstetrics and Gynaecology". Jaypee Brothers Publishers.
10. (October 1999). "[Morbidity in transsexual patients with cross-gender hormone self-treatment]". Medicina Clinica.
11. (12 January 2009). "Travesti: Sex, Gender, and Culture among Brazilian Transgendered Prostitutes". University of Chicago Press.
12. Aly. (2021-07-16). "An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations". Transfeminine Science.
13. (2007). "Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy". World Health Organization.
14. (1 January 1999). "Hormonal Contraception and Post-menopausal Hormonal Therapy". IARC.
15. (1994). "A review of "once-a-month" combined injectable contraceptives". Journal of Obstetrics and Gynaecology.
16. (March 1997). "Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate". Contraception.
17. (April 2000). "Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate". Contraception.
18. (April 1994). "Once-a-month injectable contraceptives: efficacy and reasons for discontinuation". Contraception.
19. (22 June 2005). "Current Management of the Menopause". CRC Press.
20. (2001). "Menopause – Andropause: Hormone Replacement Therapy Through the Ages". Krause & Pachernegg: Gablitz.
21. (1976). "The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London". MTP Press Limited.
22. (23 September 2010). "Mayo Clinic Internal Medicine Board Review". OUP USA.
23. (June 2010). "Estrogen as a Presumed Risk Factor for Prolactinoma in a Male-to-Female Transsexual Patient.". Endocrine Reviews.
24. (July 2010). "Estradiol enantate First report of prolactinoma, in a transsexual.". Reactions.
25. (September 1990). "Clinical use of oestrogens and progestogens". Maturitas.
26. (February 2001). "Role of cytochrome P450 in estradiol metabolism in vitro". Acta Pharmacologica Sinica.
27. (March 1995). "IX International Congress. Session 22 Long-Acting Contraception II. Abstracts. Experiences with dihydroxyprogesterone acetophenide (DHPA) 150 mg plus estradiol enanthate (E2EN) 10 mg as a once a month injectable contraceptive in Latin America". Advances in Contraception.
28. (July 1990). "Multicentred clinical study of the metabolic effect of the monthly injectable contraceptive containing dihydroxyprogesterone acetophenide 150 mg + estradiol enanthate 10 mg". Contraception.
29. Oliva Filho, W. M., & Santos, N. da C. (1992). Efeitos na coagulação sanguinea em usuárias da associação acetofenido de dihidroxiprogesterona 150mg e enantato de estradiol 10mg como metodo anticoncepcional injetavel. Universidade de São Paulo, São Paulo. https://bdpi.usp.br/item/000736190
30. (2018). "Risco de doenca tromboliticas apos o uso de algestona acetofenida e enantato de estradiol". Revista de Patologia do Tocantins.
31. (November 1986). "Estrogenic activities of estradiol enantate and ethinylestradiol compared at a clinical level". Arzneimittel-Forschung.
32. (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception.
33. (1959). "The Medical Annual: A Year Book of Treatment and Practitioner's Index ...". Publishing Science Group.
34. (1975). "Longacting steroid preparations". Acta Clinica Belgica.
35. (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception.
36. (1973). "Metabolic fate of a long-acting injectable estrogen-progestogen contraceptive 1,2". Contraception.
37. (June 1986). "Pharmacodynamic assessment of dihydroxyprogesterone acetophenide plus estradiol enanthate as a monthly injectable contraceptive". Contraception.
38. (June 1988). "Serum estrogens and ovulation return in chronic users of a once-a-month injectable contraceptive". Contraception.
39. (May 1989). "Estrogen-progestogen once-a-month injectable contraceptives and serum prolactin". Contraception.
40. (June 1977). "The clinical use of monthly injectable contraceptive preparations". Obstetrical & Gynecological Survey.
41. (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception.
42. (December 1997). "Current status of injectable hormonal contraception, with special reference to the monthly method". Advances in Contraception.
43. (November 1986). "Pharmacokinetic studies of estradiol enantate in menopausic women". Arzneimittel-Forschung.
44. (1999). "Menopause: Endocrinology and Management".
45. (January 1962). "The treatment of the menopause". Canadian Medical Association Journal.
46. (27 July 1999). "Menopause: Endocrinology and Management". Springer Science & Business Media.
47. "Estradiol enanthate | C25H36O3". ChemSpider.
48. (1953). "Über protrahiert wirksame Östrogene". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie.
49. (1954). "International Neurochemical Symposium Proceedings". Academic Press.
50. (1955). "Biochemistry of the Developing Nervous System: Proceedings". Academic Press.
51. (1958). "Acta Cytologica". International Academy of Cytology.
52. (1958). "Hormone derivatives of long-lasting action. I. Esters of estradiol". Annales Pharmaceutiques Françaises.
53. "Esters of cortical hormones, androgens, or esterogens by transesterification and alcoholysis".
54. (1964). "Deladroxate for the Prevention of Ovulation". Fertility and Sterility.
55. (1964). "Ovulation Inhibition with a Long-Acting Parenteral Progestogen-Estrogen Combination". Fertility and Sterility.
56. (15 September 1995). "Fertility and Sterility: A Current Overview". CRC Press.
57. (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception.
58. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
59. (2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis US.
60. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
61. (8 May 2018). "Drugs: Synonyms and Properties: Synonyms and Properties". Taylor & Francis.
62. "Estradiol: Uses, Dosage & Side Effects".
63. (2013). "Combination injectable contraceptives for contraception". The Cochrane Database of Systematic Reviews.
64. (14 April 2008). "Atlas of Contraception, Second Edition". CRC Press.
65. (6 December 2012). "Fertility Control — Update and Trends: Update and Trends". Springer Science & Business Media.
66. "Micromedex Products: Please Login".
67. (2009). "Martindale: The Complete Drug Reference". Pharmaceutical Press.
68. "Archived copy".
69. "Progestin Oral, Parenteral, Vaginal Advanced Patient Information".
70. (25 April 2012). "Drug Product Database Online Query".
71. (2005). "Clinical Gynecologic Endocrinology and Infertility". Lippincott Williams & Wilkins.